Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Aug;80(11):1786–1791. doi: 10.1038/sj.bjc.6690598

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II

C J Twelves 1, C Gardner 2, A Flavin 3, J Sludden 1, I Dennis 3, J de Bono 1, P Beale 4, P Vasey 1, C Hutchison 1, M A Macham 1, A Rodriguez 4, I Judson 4, N M Bleehen 3, for the CRC Phase I/II Committee
PMCID: PMC2363132  PMID: 10468297

Abstract

DACA, also known as XR5000, is an acridine derivative active against both topoisomerase I and II. In this phase I study, DACA was given as a 3-h intravenous infusion on 3 successive days, repeated every 3 weeks. A total of 41 patients were treated at 11 dose levels between 9 mg m−2 d−1 and the maximum tolerated dose of 800 mg m−2 day−1 . The commonest, and dose-limiting, toxicity was pain in the infusion arm. One patient given DACA through a central venous catheter experienced chest pain with transient electrocardiogram changes, but no evidence of myocardial infarction. At the highest dose levels, several patients also experienced flushing, pain and paraesthesia around the mouth, eyes and nose and a feeling of agitation. Other side-effects, such as nausea and vomiting, myelosuppression, stomatitis and alopecia, were uncommon. There was one minor response but no objective responses. DACA pharmacokinetics were linear and did not differ between days 1 and 3. The pattern of toxicity seen with DACA is unusual and appears related to the mode of delivery. It is possible that higher doses of DACA could be administered using a different schedule of administration. © 1999 Cancer Research Campaign

Keywords: phase I, cytotoxic, pharmacokinetics, topoisomerase I, topoisomerase II

Full Text

The Full Text of this article is available as a PDF (91.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abigerges D., Armand J. P., Chabot G. G., Bruno R., Bissery M. C., Bayssas M., Klink-Alakl M., Clavel M., Catimel G. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients. Anticancer Drugs. 1996 Feb;7(2):166–174. doi: 10.1097/00001813-199602000-00004. [DOI] [PubMed] [Google Scholar]
  2. Atwell G. J., Rewcastle G. W., Baguley B. C., Denny W. A. Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem. 1987 Apr;30(4):664–669. doi: 10.1021/jm00387a014. [DOI] [PubMed] [Google Scholar]
  3. Baguley B. C., Holdaway K. M., Fray L. M. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance. J Natl Cancer Inst. 1990 Mar 7;82(5):398–402. doi: 10.1093/jnci/82.5.398. [DOI] [PubMed] [Google Scholar]
  4. Baguley B. C., Zhuang L., Marshall E. Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide. Cancer Chemother Pharmacol. 1995;36(3):244–248. doi: 10.1007/BF00685854. [DOI] [PubMed] [Google Scholar]
  5. Evans S. M., Young D., Robertson I. G., Paxton J. W. Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose. Cancer Chemother Pharmacol. 1992;31(1):32–36. doi: 10.1007/BF00695991. [DOI] [PubMed] [Google Scholar]
  6. Finlay G. J., Baguley B. C. Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro. Eur J Cancer Clin Oncol. 1989 Feb;25(2):271–277. doi: 10.1016/0277-5379(89)90019-9. [DOI] [PubMed] [Google Scholar]
  7. Finlay G. J., Marshall E., Matthews J. H., Paull K. D., Baguley B. C. In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol. 1993;31(5):401–406. doi: 10.1007/BF00686155. [DOI] [PubMed] [Google Scholar]
  8. Gupta R. S., Gupta R., Eng B., Lock R. B., Ross W. E., Hertzberg R. P., Caranfa M. J., Johnson R. K. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res. 1988 Nov 15;48(22):6404–6410. [PubMed] [Google Scholar]
  9. Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M., Sakamoto S., Miura Y. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 1992 Feb 20;50(4):604–610. doi: 10.1002/ijc.2910500420. [DOI] [PubMed] [Google Scholar]
  10. Karato A., Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Oshita F., Nishio M., Kunikane H., Arioka H. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J Clin Oncol. 1993 Oct;11(10):2030–2035. doi: 10.1200/JCO.1993.11.10.2030. [DOI] [PubMed] [Google Scholar]
  11. Kaufmann S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 1991 Feb 15;51(4):1129–1136. [PubMed] [Google Scholar]
  12. Marshall E. S., Finlay G. J., Matthews J. H., Shaw J. H., Nixon J., Baguley B. C. Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst. 1992 Mar 4;84(5):340–345. doi: 10.1093/jnci/84.5.340. [DOI] [PubMed] [Google Scholar]
  13. Paxton J. W., Young D., Evans S. M., Kestell P., Robertson I. G., Cornford E. M. Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse. Cancer Chemother Pharmacol. 1992;29(5):379–384. doi: 10.1007/BF00686007. [DOI] [PubMed] [Google Scholar]
  14. Paxton J. W., Young D., Evans S. M., Robertson I. G., Kestell P. Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse. Cancer Chemother Pharmacol. 1993;32(4):320–322. doi: 10.1007/BF00686179. [DOI] [PubMed] [Google Scholar]
  15. Paxton J. W., Young D., Robertson I. G. Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans. Cancer Chemother Pharmacol. 1993;32(4):323–325. doi: 10.1007/BF00686180. [DOI] [PubMed] [Google Scholar]
  16. Schneider E., Darkin S. J., Lawson P. A., Ching L. M., Ralph R. K., Baguley B. C. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. Eur J Cancer Clin Oncol. 1988 Nov;24(11):1783–1790. doi: 10.1016/0277-5379(88)90082-x. [DOI] [PubMed] [Google Scholar]
  17. Tewey K. M., Chen G. L., Nelson E. M., Liu L. F. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem. 1984 Jul 25;259(14):9182–9187. [PubMed] [Google Scholar]
  18. Trask D. K., Muller M. T. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1417–1421. doi: 10.1073/pnas.85.5.1417. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES